Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently unde...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Exp Hematol Oncol
Hlavní autoři: Poddubskaya, Elena V., Baranova, Madina P., Allina, Daria O., Smirnov, Philipp Y., Albert, Eugene A., Kirilchev, Alexey P., Aleshin, Alexey A., Sekacheva, Marina I., Suntsova, Maria V.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127913/
https://ncbi.nlm.nih.gov/pubmed/30202637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0113-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky